利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.012 秒)

    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF
    1.
    发明授权
    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF 有权
    埃博霉素含组合及其药物用途

    公开(公告)号：EP1515750B1

    公开(公告)日：2010-08-11

    申请号：EP03757040.5

    申请日：2003-06-06

    申请人： Novartis AG ,  Novartis Pharma GmbH

    发明人： HOHNEKER, John, Arthur ,  MILLER, Julie, Ann ,  ROTHERMEL, John, David ,  WARTMANN, Markus

    IPC分类号： A61K45/06 ,  A61K31/426 ,  A61K31/427 ,  A61P35/00

    CPC分类号： C07K16/3015 ,  A61K31/426 ,  A61K31/427 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07D417/06 ,  A61K2300/00

    摘要： The invention relates to a pharmaceutical combination which comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors and S-adenosyl-methionine decarboxylase inhibitors; and (c) an epothilone derivative of formula (I), and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular, for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.

    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF
    6.
    发明公开
    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF 有权
    埃博霉素含组合及其药物用途

    公开(公告)号：EP1515750A1

    公开(公告)日：2005-03-23

    申请号：EP03757040.5

    申请日：2003-06-06

    申请人： Novartis AG ,  Novartis Pharma GmbH

    发明人： HOHNEKER, John, Arthur ,  MILLER, Julie, Ann ,  ROTHERMEL, John, David ,  WARTMANN, Markus

    IPC分类号： A61K45/06 ,  A61K39/395 ,  A61K31/426 ,  A61K31/427 ,  A61P35/00

    CPC分类号： C07K16/3015 ,  A61K31/426 ,  A61K31/427 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07D417/06 ,  A61K2300/00

    摘要： The invention relates to a pharmaceutical combination which comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors and S-adenosyl-methionine decarboxylase inhibitors; and (c) an epothilone derivative of formula (I), and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular, for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.

    TUBULIN MUTATION DIAGNOSTIC
    8.
    发明公开
    TUBULIN MUTATION DIAGNOSTIC 审中-公开
    微管蛋白突变诊断

    公开(公告)号：EP1812593A2

    公开(公告)日：2007-08-01

    申请号：EP05803956.1

    申请日：2005-11-10

    申请人： Novartis AG ,  NOVARTIS-PHARMA GMBH

    发明人： CULVER, Kenneth, Wayne ,  WARTMANN, Markus ,  LILLEBERG, Stan ,  ZHU, Jian

    IPC分类号： C12Q1/68 ,  G01N33/50 ,  C07K14/47

    CPC分类号： C12Q1/6883 ,  C07K14/47 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/68 ,  G01N33/6848 ,  G01N2800/52

    摘要： The present invention relates to methods for determining the potential of a subject to respond to a particular therapeutic agent, by determining the presence of one or more nucleotide or amino acid variants in the β-tubulin gene or protein. Also provided are methods for treating subjects whose potential to respond to a therapeutic agent has been evaluated. For use in the methods of the invention, there are provided variants of the β-­tubulin gene, variants of the β-tubulin protein, nucleic acid molecules and agents which bind to the variant β-tubulin nucleic acid molecules and variant β-tubulin protein, respectively, and kits comprising the same.

    摘要翻译： 本发明涉及通过确定β-微管蛋白基因或蛋白质中一种或多种核苷酸或氨基酸变体的存在来确定受试者对特定治疗剂作出反应的潜力的方法。 还提供了用于治疗对治疗剂有反应潜力的受试者的方法。 为了用于本发明的方法，提供了β-微管蛋白基因的变体，β-微管蛋白的变体，核酸分子和结合变体β-微管蛋白核酸分子和变体β-微管蛋白蛋白的试剂 ，以及包含它们的试剂盒。